RAPT Therapeutics’ (RAPT) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of RAPT Therapeutics (NASDAQ:RAPT) in a research note published on Tuesday, Benzinga reports.

A number of other equities research analysts also recently issued reports on RAPT. Wolfe Research restated a peer perform rating on shares of RAPT Therapeutics in a research note on Tuesday, May 14th. Barclays downgraded RAPT Therapeutics from an overweight rating to an equal weight rating and cut their price target for the company from $13.00 to $4.00 in a research note on Friday, May 10th. JPMorgan Chase & Co. cut their price target on RAPT Therapeutics from $15.00 to $13.00 and set a neutral rating for the company in a research note on Wednesday, March 27th. Finally, Guggenheim downgraded RAPT Therapeutics from a buy rating to a neutral rating in a research note on Friday, May 10th. Nine analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of Hold and an average price target of $24.67.

RAPT Therapeutics Stock Performance

NASDAQ RAPT opened at $3.34 on Tuesday. RAPT Therapeutics has a one year low of $2.61 and a one year high of $27.35. The stock has a 50-day moving average of $3.50 and a 200 day moving average of $9.97. The company has a market capitalization of $116.57 million, a price-to-earnings ratio of -1.09 and a beta of 0.36.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.01). On average, equities analysts predict that RAPT Therapeutics will post -2.93 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RAPT. China Universal Asset Management Co. Ltd. lifted its holdings in RAPT Therapeutics by 65.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,602 shares of the company’s stock worth $59,000 after purchasing an additional 2,621 shares in the last quarter. Acadian Asset Management LLC purchased a new position in RAPT Therapeutics in the 1st quarter worth approximately $97,000. Hennion & Walsh Asset Management Inc. lifted its holdings in RAPT Therapeutics by 8.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 48,525 shares of the company’s stock worth $148,000 after purchasing an additional 3,824 shares in the last quarter. EntryPoint Capital LLC purchased a new position in RAPT Therapeutics in the 1st quarter worth approximately $161,000. Finally, Los Angeles Capital Management LLC purchased a new position in RAPT Therapeutics in the 4th quarter worth approximately $233,000. 99.09% of the stock is owned by hedge funds and other institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.